merck vertex halt enrollment in trials merck &amp co and vertex pharmaceuticals inc said they will stop enrolling patients in two clinical trials for an experimental cancer drug pending further review of safety data according to vertex spokesman michael partridge a patient enrolled in one of the studies experienced a prolonged qt or irregular heartbeat mr partridge said that the patients currently enrolled in the trials will continue with the studies but no new patients will be enrolled the drug which is currently known as mk was being tested in patients with two types of leukemia 
